Combined dexmedetomidine-esketamine

Phase 3Small molecule

Combined dexmedetomidine-esketamine is one of 63 small molecule programs targeting Lung Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung CancerActive, not recruiting

DexmedetomidineRecruiting

Lung CancerPreclinical

Active, not recruiting

DexmedetomidinePhase 3

Recruiting

Competition

Competitive Landscape

206 competitors in Lung Cancer

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

33 2

Opdivo

Bristol-Myers Squibb

Phase 3

20 3

Tagrisso

AstraZeneca

Phase 3

19 4

Beyfortus

BeiGene

Phase 3

10 5

Yervoy

Bristol-Myers Squibb

Phase 3

10 6

Abraxane

Bristol-Myers Squibb

Phase 3

7 7

Imjudo

AstraZeneca

Phase 3

6 8

Tecentriq

Roche

Phase 3

6 9

Alunbrig

Takeda

Phase 3

4 10

Tarlatamab-Dznl

Amgen

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Post-ApprovalRecruiting

Dexmedetomidine

NCT06399185

Clinical

Trials by Indication[1]

Dexmedetomidine1 trial

Effect of Dexmedetomidine and Esketamine on Catheter-related Bladder Discomfort

Recruiting·PPeking University First Hospital·Phase 4·NCT06399185·1,740 enrolled

Anesthesia1 trial

Epidural Anesthesia-analgesia and Long-term Outcome

Completed·PPeking University First Hospital·N/A·NCT03012945·1,802 enrolled

Lung Cancer1 trial

Epidural Anesthesia-analgesia and Long-term Survival After Lung Cancer Surgery

Completed·PPeking University First Hospital·N/A·NCT02801409·400 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Combined dexmedetomidine-esketamine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Combined dexmedetomidine-esketamine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Combined dexmedetomidine-esketamine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Peking University First Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: PPeking University First Hospital

Combined dexmedetomidine-esketamine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Dexmedetomidine1 trial

Anesthesia1 trial

Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News